Clinical OMICS

MAR-APR 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/958440

Contents of this Issue

Navigation

Page 39 of 51

In the Lab 38 Clinical OMICs March/April 2018 www.clinicalomics.com Dovetail Genomics, LLC, a company that uses proximity ligation and advanced informatics for genomic solutions, have introduced Dovetail Hi-C and Fix-C with Selva SV Detection Software as a Service. Applications of the tech- nique range from oncology and undiagnosed disease research to retrospective analysis of clinical trials, the com- pany said. "Historically, there has been no way to gain structural variation information from formalin-fixed paraffin-embed- ded (FFPE) samples," said Veronica Mankinen, vice pres- ident of commercial operations at Santa Cruz, CA-based Dovetail. "The goal is to be able to use these millions of global FFPE retrospective studies." Though widely available, FFPE cancer tissue samples store a vast supply of genomic information, but because the DNA significantly degrades in a FFPE sample, it's "difficult or impossible to conduct broad interrogations of clinically important large-scale structural rearrangements," the com- pany said. "Until today, our business has primarily been focused on providing the highest qual- ity genome assemblies to the plant and animal communities," said Dovetail CEO Todd Dickin- son. "With this new service, and the many advances that will fol- low throughout the year, we are delighted to be able to bring the same long-range genomic insights to bear on human health." Arul M. Chinnaiyan, M.D., director of the Michigan Cen- ter for Translational Pathology, focuses his research on functional genomic, proteomic and bioinfor- matics approaches to study cancer for the purposes of understanding cancer biology, as well as to dis- cover clinical biomarkers. Chinnai- yan said using Dovetail's products, his team has been able to validate existing findings and discovered the structural variants that they suspected, but have been unable to detect using other tools. Geneticist Helio Costa, Ph.D., instructor of pathology and biomedical data science and assistant lab director of molecular pathology at Stanford University has been pilot- ing Fix-C with Selva software to see if the application can be used to advance precision medicine in cancer treatment. When Costa and his team profiled FFPE tumor tissue using Dovetail's technology, they discovered gene signatures not discernable by other approaches. "This pilot shows promise for what this method could identify," he said. "It worked rather well." Dovetail said it is now accepting a limited number of customers into its Early Access Development Program for TAD Analysis, an application of the Dovetail Hi-C data type that enables researchers to evaluate the three-di- mensional structure of the genome and genome folding. — Diana Manos Dovetail Offers New Way to Access FFPE Samples TEK IMAGE/SCIENCE PHOTO LIBRARY / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAR-APR 2018